[EN] 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER [FR] DÉRIVÉS DE 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHÉNYL)-PYRIDIN-3-YL)MÉTHANONE ET COMPOSÉS SIMILAIRES SERVANT D'INHIBITEURS DE CYP11A1 POUR LE TRAITEMENT DU CANCER DE LA PROSTATE
The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
本发明涉及吡啶并嗪酮和相关化合物,它们是PARP7的抑制剂,并且在癌症治疗中很有用。
[EN] HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER<br/>[FR] URÉES SUBSTITUÉES HÉTÉROCYCLIQUES, DESTINÉES À ÊTRE UTILISÉES CONTRE LE CANCER
申请人:ARTIOS PHARMA LTD
公开号:WO2020030925A1
公开(公告)日:2020-02-13
The application relates to heterocyclic urea derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
该应用涉及杂环脲衍生物及其在癌症治疗和预防中的应用,以及含有这些衍生物的组合物和它们的制备方法。
[EN] PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
申请人:MERCK SHARP & DOHME
公开号:WO2022056051A1
公开(公告)日:2022-03-17
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.